$21 Mln
$-9 Mln
--
As on 02-Oct-2023 16:00 EDT
$0.06
•
6.97%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Unicycive Therapeutics Inc (UNCY)
| 70.35 | 14.99 | -28.13 | 55.92 | -- | -- | -- |
|
S&P BSE Sensex*
| 7.86 | 0.36 | 1.40 | 14.28 | 19.25 | 12.43 | 12.89 |
|
#
| -- | -- | -- | -- | -- | -- | -- |
|
2022
|
|
|---|---|
|
Unicycive Therapeutics Inc (UNCY)
| -73.79 |
|
S&P BSE Sensex
| 4.44 |
|
S&P BSE Sensex
| 4.44 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
The total asset value of Unicycive Therapeutics Inc (UNCY) stood at $ 43 Mln as on 31-Mar-23
The share price of Unicycive Therapeutics Inc (UNCY) is $0.92 (NASDAQ) as of 02-Oct-2023 16:00 EDT. Unicycive Therapeutics Inc (UNCY) has given a return of 55.92% in the last 1 years.
Unicycive Therapeutics Inc (UNCY) has a market capitalisation of $ 21 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.
The P/B ratio of Unicycive Therapeutics Inc (UNCY) is 2.44 times as on 02-Jun-2023, a -0.04% premium to its peers’ median range of 2.54 times.
Since, TTM earnings of Unicycive Therapeutics Inc (UNCY) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Unicycive Therapeutics Inc (UNCY) and enter the required number of quantities and click on buy to purchase the shares of Unicycive Therapeutics Inc (UNCY).
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
The CEO & director of Dr. Shalabh K. Gupta M.D., MPA. is Unicycive Therapeutics Inc (UNCY), and CFO & Sr. VP is Mr. John W. Townsend CPA.
The promoters of Unicycive Therapeutics Inc (UNCY) have pledged 0% of the total equity as on Dec-22.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
498
|
|
|
497
|
|
|
392
|
|
|
383
|
| Unicycive Therapeutics Inc (UNCY) | Ratios |
|---|---|
|
Return on equity(%)
|
-524.06
|
|
Return on capital employed(%)
|
--
|
|
Debt-to-equity ratio
|
0
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Unicycive Therapeutics Inc (UNCY) was $-9 Mln.
$21.17 Mln
$1.63 Mln
$-9.19 Mln
$24.33 Mln
$0.99 Mln
High
$0.40 - 2.87
15,233,800
NASDAQ: UNCY
Los Altos, CA
https://www.unicycive.com
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis;... and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. Read more
Learn the principles, mindset and tools you need to become a successful Mutual Fund and Stock investor from the masters who have been doing this for decades.
Use India's most advanced investment tracker to track, analyse and get updates and insights on your investments.
Get an analysis of your portfolio along with actionable, general tips and insights, guidance on where to invest based on your goals, and experts' opinions on individual Mutual Funds and Stocks.
Value Research offers the most advanced and detailed data & analytics available on Mutual Funds and Stocks. Sign up and unlock the power yourself.
Unlimited access to advice from India's top experts
The most comprehensive analysis of funds and stocks in India
A holistic portfolio manager to help track all your investments easily
And much more, like guides, tools, webinars, videos and eBooks.
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
